CVRx to Present at Goldman Sachs Healthcare Conference Amid Barostim Expansion
Event summary
- CVRx to present at Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.
- Presentation scheduled for 8:00 a.m. ET, webcast available on CVRx's investor relations page.
- Barostim, CVRx's neuromodulation device, is FDA-approved for heart failure and CE Mark-approved in the EU.
- Company focuses on autonomic nervous system modulation for cardiovascular diseases.
The big picture
CVRx's presentation at the Goldman Sachs conference comes as neuromodulation gains traction in cardiovascular care. The company's Barostim device is one of the few FDA-approved neuromodulation therapies for heart failure, positioning it in a niche but growing segment of the medical device market. The strategic focus now shifts to commercial execution and expanding into resistant hypertension, where regulatory approvals provide a competitive edge.
What we're watching
- Commercialization Pace
- How CVRx will scale Barostim adoption post-FDA and CE Mark approvals.
- Regulatory Dynamics
- Whether the FDA Breakthrough Device designation will accelerate reimbursement discussions.
- Market Expansion
- The pace at which CVRx can penetrate the resistant hypertension market in the EU.
Related topics